...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Update

We have heard from Don numerous times that these types of cancer  trials are much shorter in length and since they are unblinded data should be announced much quicker than Cardio/diabetis trials, So why have we not heard any major PR from Zenith on the Trial, Surely, if the results are great they would want to annouce what is occurring in the trial.  unless a deal is in the works and the party or parties involved don't want any data on the current trial, yet they have released some info from the past biotech conferences,  so what gives,....   inquiring minds want to know,  its been too long and retail shareholders deserve better..

Share
New Message
Please login to post a reply